Clinical Trial Update: Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for alprostadil liposomes for injection targeting lower extremity arteriosclerosis obliterans in peripheral artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lower Extremity Arteriosclerosis Obliterans
• Peripheral Artery Disease

Drugs mentioned

• Alprostadil Liposomes for Injection (alprostadil liposome)

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Peripheral Artery Disease | Phase 2 | Status: UNKNOWN